Global Gamma Knife Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Gamma Knife Market Size

• The global gamma knife market size was valued at USD 468.22 million in 2024 and is expected to reach USD 691.78 million by 2032, at a CAGR of 5.00% during the forecast period
• This growth is driven by rising prevalence of brain tumours

Gamma Knife Market Analysis

• Gamma Knife technology plays a crucial role in non-invasive neurosurgery, enabling highly precise radiation delivery to brain lesions while minimizing damage to surrounding healthy tissue, significantly improving patient recovery and outcomes
• The demand for gamma knife systems is rising due to increasing incidence of neurological disorders, growing preference for minimally invasive procedures, and expanding application of stereotactic radiosurgery in treating brain tumors, AVMs, and trigeminal neuralgia
• North America is expected to dominate the gamma knife market with the largest market share of 44.87%, driven by advanced neurosurgical centers, high healthcare spending, supportive reimbursement policies, and rapid adoption of precision oncology technologies
• Asia-Pacific is projected to register the highest growth rate in the gamma knife market during the forecast period, fueled by rising healthcare infrastructure investments, improved access to specialized treatments, and increased awareness of non-surgical brain treatment options across countries such as India, China, and Japan
• The brain metastasis segment is expected to dominate the usability segment with the largest market share of 46.94% in 2025, due to the rising incidence of brain metastases, the effectiveness of gamma knife in delivering targeted radiation with minimal damage to healthy tissue, and growing preference for non-invasive treatment options

Report Scope and Gamma Knife Market Segmentation

Gamma Knife Market Trends

“Growing Shift toward Outpatient Radiosurgery Settings”

• A significant trend in the gamma knife market is the increasing preference for outpatient-based stereotactic radiosurgery procedures due to reduced hospital stays, lower costs, and faster recovery times for patients
• Healthcare systems are transitioning to day-care models for brain tumor treatments and functional neurological procedures, supported by the precision and safety of gamma knife technology
• This trend is also aligned with healthcare cost-containment strategies and patient demand for convenient, non-invasive care delivery
  • For instance, in 2024, Mayo Clinic expanded its outpatient neurosurgery unit with a dedicated Gamma Knife suite, enabling same-day treatment and discharge for eligible patients
• The shift toward outpatient settings is driving demand for compact, efficient gamma knife systems and reshaping service delivery in neurology and oncology departments

Gamma Knife Market Dynamics

Driver

“Rising Prevalence of Neurological Disorders and Brain Tumors”

• The growing incidence of conditions such as glioblastoma, brain metastases, acoustic neuroma, and arteriovenous malformations (AVMs) is significantly increasing demand for gamma knife radiosurgery
• An aging global population and improved imaging diagnostics have led to earlier detection of brain disorders, enhancing the suitability of gamma knife procedures for both malignant and non-malignant conditions
• As a result, neurosurgical centers are investing more in advanced radiosurgery tools to address the rising clinical burden of neuro-oncological and vascular brain diseases
  • For instance, in 2023, the World Health Organization (WHO) reported a 12% rise in global brain tumor cases over the past decade, pushing hospitals to expand Gamma Knife access
• This driver is reinforcing the role of gamma knife as a critical component of the neuro-oncology care continuum

Opportunity

“Expansion into Emerging Markets with Growing Healthcare Infrastructure”

• Developing nations are witnessing a surge in public and private healthcare investments, creating new opportunities for the deployment of gamma knife systems
• Government-backed healthcare reforms, improving insurance coverage, and rising awareness of non-invasive cancer treatments are making advanced radiosurgery more accessible in countries such as India, Brazil, and South Africa
• Local manufacturing and regional partnerships are helping reduce equipment costs and streamline regulatory approvals for gamma knife systems in these markets
  • For instance, in 2024, Elekta partnered with India-based Fortis Healthcare to expand Gamma Knife installations across Tier-2 cities, increasing access to precision radiosurgery
• This opportunity could significantly increase market penetration and patient reach in under-served regions globally

Restraint/Challenge

“Limited Skilled Workforce for Gamma Knife Operation and Planning”

• A major challenge in the gamma knife market is the shortage of trained neurosurgeons, radiation oncologists, and medical physicists proficient in stereotactic radiosurgery procedures
• The complexity of treatment planning and dose delivery with gamma knife systems demands specialized training, which is lacking in many developing and mid-tier hospitals
• This shortage can delay adoption and limit patient throughput, especially in facilities without dedicated radiosurgery teams
  • For instance, in 2023, a survey by the International Stereotactic Radiosurgery Society (ISRS) revealed that over 40% of Gamma Knife centers in Southeast Asia faced staffing limitations that reduced their patient capacity
• Addressing this challenge through global training programs and AI-assisted treatment planning is essential for maximizing clinical utility and market expansion

Gamma Knife Market Scope

The market is segmented on the basis of disease indications, anatomy, end-user, and range.

In 2025, the brain metastasis is projected to dominate the market with a largest share in material segment

The brain metastasis segment is expected to dominate the gamma knife market with the largest market share of 46.94% in 2025, due to the rising incidence of brain metastases, the effectiveness of gamma knife in delivering targeted radiation with minimal damage to healthy tissue, and growing preference for non-invasive treatment options.

The high-end gamma knife is expected to account for the largest share during the forecast period in Range segment

In 2025, the high-end gamma knife segment is expected to dominate the market with the largest market share of 89.15%, driven by its advanced precision, superior treatment outcomes, reduced side effects, and increasing adoption by specialized neurosurgical centers seeking cutting-edge, non-invasive solutions for complex brain disorders.

Gamma Knife Market Regional Analysis

“North America Holds the Largest Share in the Gamma Knife Market”

• North America is expected to dominate the global gamma knife market with the largest market share of 32.45%, driven by the presence of advanced neurosurgical infrastructure, high healthcare spending, and a strong focus on minimally invasive treatment approaches for neurological conditions
• The U.S. leads the region due to widespread availability of cutting-edge gamma knife centers, increasing cases of brain tumors and neurological disorders, and proactive reimbursement policies supporting stereotactic radiosurgery
• Strategic partnerships between medical device companies and research institutions, along with continued FDA approvals of advanced models such as gamma knife Icon, are set to reinforce North America’s market leadership throughout the forecast period

 “Asia-Pacific is Projected to Register the Highest CAGR in the Gamma Knife Market”

• Asia-Pacific is expected to witness the highest compound annual growth rate (CAGR) in the gamma knife market, fueled by growing awareness of non-invasive treatment alternatives, rising geriatric population, and a surge in neurosurgical procedures
• Countries such as China, India, and Japan are at the forefront, supported by large patient populations, increasing government investments in high-precision medical technologies, and expanding medical tourism
• Government-led healthcare modernization initiatives, such as China’s Healthy China 2030 and Japan’s reforms in robotic and image-guided surgery, are boosting the adoption of gamma knife systems across tertiary hospitals and cancer centers

Gamma Knife Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Elekta (Sweden)
• Varian (U.S.)
• Accuray Incorporated (U.S.)
• Vision RT Ltd. (U.K.)
• MASEP Medical Science & Technology Development Co. (China)
• Nordion Inc. (Canada)
• Brainlab AG (Germany)
• CQ Medical (U.S.)
• ONO SOKKI CO., LTD (India)
• Panacea Medical Technologies Pvt. Ltd. (India)
• Akesis, Inc. (U.S.)
• Fortis Healthcare (India)
• Corewell Health (U.S.)

Latest Developments in Global Gamma Knife Market

• In June 2024, Fortis Memorial Research Institute introduced the Gamma Knife Esprit, marking its debut in South Asia. This state-of-the-art Leksell Gamma Knife system ushers in a new era of non-invasive, high-precision treatments for both malignant and benign brain tumors, as well as other neurological disorders. This launch strengthens Fortis’ position as a leader in advanced neurosurgical care in the region
• In April 2024, the AdventHealth Neuroscience Institute became the first center in Central Florida to deploy the Elekta Esprit Gamma Knife for brain treatments. This next-generation SRS system delivers precise ablative radiation with minimal impact on healthy tissues. The installation highlights growing adoption of advanced radiosurgical systems in U.S. regional hospitals
• In May 2022, Elekta launched the Elekta Esprit, a next-generation Gamma Knife platform designed to deliver personalized radiosurgery with sub-millimeter accuracy and rapid treatment planning under 60 seconds. It also features enhanced visualization, remote access, and collaboration tools for clinicians. This product launch expanded Elekta’s advanced radiosurgery portfolio and strengthened its market position
• In October 2021, Panacea Medical Technologies Pvt. Ltd. received FDA 510(k) clearance for its next-generation SBRT-enabled linear accelerator, built on a ring gantry platform. This innovation brings precision radiotherapy closer to a wider set of clinical applications. The clearance supported Panacea’s entry into the U.S. precision radiotherapy market
• In May 2020, Elekta introduced the Leksell Gamma Knife Lightning, the only fully integrated computerized treatment management system for Gamma Knife at the time. It featured plan optimization based on variables such as beam-on time. This innovation enhanced clinical efficiency and planning precision in radiosurgery practices

SKU-10606